Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 115

1.

Comprehensive Antiretroviral Restriction Factor Profiling Reveals the Evolutionary Imprint of the ex Vivo and in Vivo IFN-β Response in HTLV-1-Associated Neuroinflammation.

Leal FE, Menezes SM, Costa EAS, Brailey PM, Gama L, Segurado AC, Kallas EG, Nixon DF, Dierckx T, Khouri R, Vercauteren J, Galvão-Castro B, Saraiva Raposo RA, Van Weyenbergh J.

Front Microbiol. 2018 May 22;9:985. doi: 10.3389/fmicb.2018.00985. eCollection 2018.

2.

IFN-β regulates Th17 differentiation partly through the inhibition of osteopontin in experimental autoimmune encephalomyelitis.

Zhao Q, Cheng W, Xi Y, Cao Z, Xu Y, Wu T, Li C, Niu X, Chen G.

Mol Immunol. 2018 Jan;93:20-30. doi: 10.1016/j.molimm.2017.11.002. Epub 2017 Nov 8.

PMID:
29127843
3.

Sativex® effects on promoter methylation and on CNR1/CNR2 expression in peripheral blood mononuclear cells of progressive multiple sclerosis patients.

Santoro M, Mirabella M, De Fino C, Bianco A, Lucchini M, Losavio F, Sabino A, Nociti V.

J Neurol Sci. 2017 Aug 15;379:298-303. doi: 10.1016/j.jns.2017.06.017. Epub 2017 Jun 15.

PMID:
28716266
4.

Genetic burden of MS risk variants distinguish patients from healthy individuals but are not associated with disease activity.

Søndergaard HB, Petersen ER, Magyari M, Sellebjerg F, Oturai AB.

Mult Scler Relat Disord. 2017 Apr;13:25-27. doi: 10.1016/j.msard.2017.01.015. Epub 2017 Jan 31.

PMID:
28427696
5.

TRAIL gene expression analysis in multiple sclerosis patients.

Taheri M, Nemati S, Movafagh A, Saberi M, Mirfakhraie R, Eftekharian MM, Arsang-Jang S, Rezagholizadeh A, Sayad A.

Hum Antibodies. 2016 May 20;24(1-2):33-8. doi: 10.3233/HAB-160291.

PMID:
27472871
6.

Immune response genes receptors expression and polymorphisms in relation to multiple sclerosis susceptibility and response to INF-β therapy.

Karam RA, Rezk NA, Amer MM, Fathy HA.

IUBMB Life. 2016 Sep;68(9):727-34. doi: 10.1002/iub.1530. Epub 2016 Jun 27.

7.

Screening and characterization of molecules that modulate the biological activity of IFNs-I.

Bürgi M, Zapol'skii VA, Hinkelmann B, Köster M, Kaufmann DE, Sasse F, Hauser H, Etcheverrigaray M, Kratje R, Bollati-Fogolín M, Oggero M.

J Biotechnol. 2016 Sep 10;233:6-16. doi: 10.1016/j.jbiotec.2016.06.021. Epub 2016 Jun 23.

PMID:
27346232
8.

Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta.

Hermanrud C, Ryner M, Luft T, Jensen PE, Ingenhoven K, Rat D, Deisenhammer F, Sørensen PS, Pallardy M, Sikkema D, Bertotti E, Kramer D, Creeke P, Fogdell-Hahn A; ABIRISK Consortium.

J Immunol Methods. 2016 Mar;430:1-9. doi: 10.1016/j.jim.2016.01.004. Epub 2016 Jan 11.

PMID:
26779831
9.

Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis.

Clarelli F, Liberatore G, Sorosina M, Osiceanu AM, Esposito F, Mascia E, Santoro S, Pavan G, Colombo B, Moiola L, Martinelli V, Comi G, Martinelli-Boneschi F.

Pharmacogenomics J. 2017 Jan;17(1):84-91. doi: 10.1038/tpj.2015.85. Epub 2015 Dec 8.

PMID:
26644207
10.

Targeted mutations in Val101 and Arg27 interferon beta protein increase its transcriptional and translational activities.

Kay M, Hasan-Abad AM, Hojati Z, Korbekandi H.

Cytokine. 2016 Feb;78:1-6. doi: 10.1016/j.cyto.2015.11.019. Epub 2015 Nov 23.

PMID:
26615566
11.

Gene set differential analysis of time course expression profiles via sparse estimation in functional logistic model with application to time-dependent biomarker detection.

Kayano M, Matsui H, Yamaguchi R, Imoto S, Miyano S.

Biostatistics. 2016 Apr;17(2):235-48. doi: 10.1093/biostatistics/kxv037. Epub 2015 Sep 28.

PMID:
26420796
12.

Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene.

Bertoli D, Serana F, Sottini A, Cordioli C, Maimone D, Amato MP, Centonze D, Florio C, Puma E, Capra R, Imberti L.

PLoS One. 2015 Aug 18;10(8):e0135441. doi: 10.1371/journal.pone.0135441. eCollection 2015.

13.

IFN-β Selectively Inhibits IL-2 Production through CREM-Mediated Chromatin Remodeling.

Otero DC, Fares-Frederickson NJ, Xiao M, Baker DP, David M.

J Immunol. 2015 Jun 1;194(11):5120-8. doi: 10.4049/jimmunol.1403181. Epub 2015 Apr 17.

14.

Effects of disruption of the nucleotide pattern in CRID element and Kozak sequence of interferon β on mRNA stability and protein production.

Kay M, Hojati Z, Heidari M, Bazi Z, Korbekandi H.

Autoimmunity. 2015;48(5):336-43. doi: 10.3109/08916934.2015.1022164. Epub 2015 Mar 23.

PMID:
25799196
15.

In vivo maintenance of human regulatory T cells during CD25 blockade.

Huss DJ, Mehta DS, Sharma A, You X, Riester KA, Sheridan JP, Amaravadi LS, Elkins JS, Fontenot JD.

J Immunol. 2015 Jan 1;194(1):84-92.

16.

Multiple sclerosis: effects of IFN-β treatment on vitamin D levels in multiple sclerosis are modified by genetic variants.

Fyfe I.

Nat Rev Neurol. 2014 Dec;10(12):672. doi: 10.1038/nrneurol.2014.210. Epub 2014 Nov 4. No abstract available.

PMID:
25366113
17.

Induction of a unique isoform of the NCOA7 oxidation resistance gene by interferon β-1b.

Yu L, Croze E, Yamaguchi KD, Tran T, Reder AT, Litvak V, Volkert MR.

J Interferon Cytokine Res. 2015 Mar;35(3):186-99. doi: 10.1089/jir.2014.0115. Epub 2014 Oct 20.

18.

Modulating effects of WT1 on interferon-β-vitamin D association in MS.

Lin R, Taylor BV, Charlesworth J, van der Mei I, Blizzard L, Stewart N, Ponsonby AL, Dwyer T, Pittas F, Simpson S Jr.

Acta Neurol Scand. 2015 Apr;131(4):231-9. doi: 10.1111/ane.12315. Epub 2014 Oct 14.

PMID:
25312909
19.

Hereditary diffuse leukoencephalopathy with spheroids with phenotype of primary progressive multiple sclerosis.

Sundal C, Baker M, Karrenbauer V, Gustavsen M, Bedri S, Glaser A, Myhr KM, Haugarvoll K, Zetterberg H, Harbo H, Kockum I, Hillert J, Wszolek Z, Rademakers R, Andersen O.

Eur J Neurol. 2015 Feb;22(2):328-333. doi: 10.1111/ene.12572. Epub 2014 Oct 13.

20.

A multiple sclerosis-associated variant of CBLB links genetic risk with type I IFN function.

Stürner KH, Borgmeyer U, Schulze C, Pless O, Martin R.

J Immunol. 2014 Nov 1;193(9):4439-47. doi: 10.4049/jimmunol.1303077. Epub 2014 Sep 26.

Supplemental Content

Loading ...
Support Center